Feature Article

Comorbidities in Rosacea: Considerations for Diagnosis and Treatment


Like most autoimmune diseases, rosacea involves dysregulation of the inflammatory response and may share pathogenesis with several common comorbidities, including cardiovascular, psychiatric, gastrointestinal, autoimmune, and neurologic conditions.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Disease Severity, Demographics Play Important Role in Rosacea Management


Self-assessment severity scores were significantly higher in participants age <60 compared with participants age ≥60.

Topical Minocycline Foam Safe, Effective for Papulopustular Rosacea


The researchers concluded that FMX103 is a safe and effective therapy for facial papulopustular rosacea.

Clarifying Disease Characteristics of Papulopustular Rosacea


With the causative role of the Demodex mite in the development of rosacea not widely accepted, the investigators sought to explore differences in Demodex densities based on clinical characteristics historically associated with PPR and demodicosis.

Oxymetazoline Effective for Long-Term Treatment of Rosacea-Associated Facial Erythema


Throughout the 52-week study period, patients applied a pea-sized amount of the medication in a thin layer that covered the entire face, including the forehead, cheeks, nose, and chin, at the same time every morning.

Topical Oxymetazoline Effective for Reducing Rosacea-Associated Erythema


In REVEAL 1 and REVEAL 2, participants were randomly assigned to treatment with oxymetazoline or vehicle once daily for 29 days and were followed for 28 days post-treatment.

CV Risk Stratification Utilizing Validated Assessment Scales in Rosacea

Cardiovascular frequency risk was assessed using the Framingham risk score and systemic coronary risk evaluation.

Generic Rosacea Treatment Wins Tentative FDA Approval


The FDA has given tentative approval to Perrigo's ivermectin cream, which is indicated to treat inflammatory lesions of rosacea.

Increased Risk for Incident Rosacea Associated With Obesity in Women


Investigators believe this is the first longitudinal study to observe the risk for incident rosacea and obesity measurements other than body mass index only.

Sign up for Newsletters